Ro Partners with Novo Nordisk for Wegovy® Pill Launch
Ro, a leader in direct-to-patient healthcare, is launching the Wegovy® pill in collaboration with Novo Nordisk. This launch marks a significant milestone as it allows patients to easily access the first oral GLP-1 weight loss medication at the most affordable price.
A Seamless Healthcare Experience
With this new offering, patients can visit Ro's platform to get the Wegovy® pill, making it simpler than ever to engage with obesity treatments. Ro has been collaborating with Novo Nordisk since April 2025, contributing to their efforts to provide direct-to-patient services that focus on convenience and accessibility.
Addressing Obesity Effectively
Dave Moore, Executive Vice President at Novo Nordisk for U.S. Operations, highlights the importance of making obesity treatment accessible to everyone. The collaboration with Ro enhances their ability to reach patients who may have been hesitant to seek obesity medications due to administration preferences. Through Ro’s integrated platform, eligible patients can navigate from diagnosis to delivery seamlessly.
Research Backing Innovative Solutions
Ro recently published a pioneering study on the outcomes of semaglutide treatment via telehealth. This peer-reviewed research demonstrated that patients using Ro's services achieved comparable results in weight loss and safety to those seen in traditional clinical trials. Participants in the study experienced an impressive average weight loss of 16.6% over a period of 68 weeks.
Innovative Models for Better Outcomes
According to Ro's co-founder and CEO Zach Reitano, the Wegovy® pill's launch from day one through Ro signifies an innovative step forward in the obesity treatment market. Ro's model empowers patients by delivering experiences akin to those in clinical trials while also ensuring they pay the lowest possible prices for these FDA-approved therapies.
Comprehensive Care Options
Ro offers an extensive obesity care formulary, which includes both cash pay and insurance-eligible alternatives. Patients have the option to have their prescriptions delivered to their homes or to pick them up at a pharmacy. With Ro's GLP-1 Insurance Checker, patients can verify their benefits for free, ensuring they receive the medication they need at the best price.
About Ro and Their Commitment to Patients
Ro aims to help patients achieve their health goals through accessible and effective care. Their vertically integrated platform ensures a comprehensive healthcare experience, supporting patients from diagnosis to medication delivery. Since its inception in 2017, Ro has reached millions of patients, providing services even in areas with limited access to primary healthcare.
For those interested in Ro's Body Membership and their broad range of GLP-1 options, further information is available on their platform.
Frequently Asked Questions
What is Wegovy® and how does it help with weight loss?
Wegovy® is an oral GLP-1 medication designed to aid weight loss by affecting how the body regulates appetite and food intake.
How does Ro ensure quality care for its patients?
Ro combines an integrated healthcare platform that streamlines the process from diagnosis to treatment, ensuring high standards of patient care.
Can I verify my insurance coverage for the Wegovy® pill?
Yes, Ro provides an Insurance Checker to help you determine your benefits for medications, enabling access to the most affordable options.
Is the Wegovy® pill available in all locations?
The Wegovy® pill is designed to be accessible nationwide via Ro’s platform, allowing patients to obtain it conveniently.
What sets Ro apart from other healthcare providers?
Ro’s direct-to-patient model and vertical integration provide a unique approach to healthcare that prioritizes patient outcomes and affordability.
